Resources
39 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/25/2022 (updated 4/26/2024)
A guidebook from the Substance Abuse and Mental Health Services Administration describes various methods of adapting evidence-based practices for substance use disorder (SUD) to meet the needs of populations who experience barriers in receiving behavioral health services due to a variety of factors including race, ethnicity, geography, income, sexual orientation, and disability.
Posted 5/10/2021 (updated 4/10/2024)
Participants will be provided an overview on how to appropriately document, code and bill for encounters throughout the SUD/OUD continuum of care following CMS billing rules for FQHCs/RHC. An overview of the opportunities and challenges associated with MAT reimbursement mechanisms including coding and billing for Medicare, managed care, Medicaid, and other third-party payors will also be presented as will a brief description of revenue options for reporting Transitional Care Management, Virtual Communication Services, Telehealth, and other care management services such as Behavioral Health Integration and the Psychiatric Collaborative Care Model.
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 4/26/2021 (updated 4/10/2024)
The Evidence-Based Resource Guide Series is a comprehensive set of modules with resources to improve health outcomes for people at risk for, with, or recovering from mental and/or substance use disorders. It is designed for practitioners, administrators, community leaders, and others considering an intervention for their organization or community.
Posted 3/25/2021 (updated 4/5/2024)
Documentation, Coding, and Billing for SUD/OUD via Medication-Assisted Treatment (MAT): A Rural and Community Health Focus
The presenter will outline the steps needed to effectively document, code, and bill for services including screening for SUD/OUD and providing care during the induction, stabilization, and maintenance phases of MAT. Individual state Medicaid issues are too numerous and will not be specifically referred to on a state-by-state basis.
Posted 2/17/2021 (updated 4/4/2024)
New Series of Advisories on Substance Use Disorder Treatment.
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 10/14/2021 (updated 4/3/2024)
Presenters reviewed resources available to rural grantees through their respective agencies.
Posted 12/9/2020 (updated 4/3/2024)
State policymakers are interested in learning about the most effective treatments to address OUD and avoid unintended consequences such as overdose events, mortality from overdose, and use of illicit and unregulated drugs. This article describes the lack of evidence surrounding the use of Medically Supervised Withdrawal as a standalone “treatment.”
Posted 9/1/2021 (updated 4/2/2024)